Real World Evidence Solutions Market worth $10.83 billion by 2030 with 14.8% CAGR | MarketsandMarkets™
DELRAY BEACH, Fla., Aug. 19, 2025 /PRNewswire/ -- The global Real World Evidence Solutions Market, valued at US$4.74 billion in 2024,...
Neurology
Ryght AI Partners with Global CRO Biorasi to Deliver AI-Powered Feasibility Solutions to Biotech and Biopharma Sponsors
Advanced AI Platform Enables More Accurate Site Selection and Faster Study Startup Across Key Therapeutic Areas Partnership brings real-time site...
Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes
LAVAL, QC / ACCESS Newswire / August 15, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company")...
Hemostemix’s Expands its Marketing Team Focused on Sales in Florida
Calgary, Alberta--(Newsfile Corp. - August 14, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), an autologous stem cell...
Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights
Following constructive FDA feedback on its proposed statistical analysis plan, Clene plans to analyze the neurofilament light data from its...
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy
BOSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company...
Cassava Reports Q2 2025 Financials Results and Provides Business Update
Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for the...
Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference
CNSide® can quantify leptomeningeal metastases (LM) over time and monitor changes in the expression of multiple targetable mutations CNSide® may...
Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT – Advancing Breakthrough Therapy for Chronic Lower Back Pain
PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on...
Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT – Advancing Breakthrough Therapy for Chronic Lower Back Pain
PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on...
Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution
Strategy for sustainable profitable growth progressing as planned with improving revenue mix and ahead-of-plan cost reductionsReporting segment formerly known as...
Global Contract Manufacturing Market on Track for $968.7 Billion by 2030
"With rising demand across pharma, electronics, and automotive sectors, contract manufacturing offers cost savings, supply chain stability, and access to...
The Dawn of Medical Superintelligence: ATLAS AI
In a Breakthrough Study ATLAS AI Outperforms Clinicians and ChatGPT in Medical Diagnoses While Slashing Unnecessary Tests LOS ANGLES, Aug....
CRC Becomes Accredited Medidata Rave® EDC Partner
ST. PETERSBURG, Fla., Aug. 12, 2025 /PRNewswire/ -- Cognitive Research Corporation (CRC), a full-service CRO specializing in neuroscience, has officially...
SamaCare Ranks No. 578 on the 2025 Inc. 5000 List of America’s Fastest-Growing Private Companies
This Marks SamaCare's Second Time on the List, Ranking in the top 12% of America's Fastest-Growing Companies SAN FRANCISCO, Aug. 12,...
FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology...
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
– Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment...
ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance
Generated record quarterly net revenues of $211.4 million, representing year-over-year growth of 53.1% on a reported basis and 37.0% on...
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025
Tokyo, Japan and Cambridge, UK, 8 August 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update...
Creyos Expands Session Notes to Turn Cognitive Health Testing Into Timely Clinical Action
Developed by world-renowned neuroscientist Professor Adrian Owen, Creyos helps providers detect cognitive impairment through a scientifically validated brain health assessment platform...